Rajangam Kanya 4
4 · Senti Biosciences, Inc. · Filed Feb 6, 2025
Insider Transaction Report
Form 4
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Transactions
- Sale
Common Stock
2025-02-04$4.07/sh−1,297$5,279→ 8,803 total - Sale
Common Stock
2025-02-06$4.37/sh−182$795→ 8,621 total
Footnotes (1)
- [F1]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.